Navigation Links
Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Date:9/17/2007

NEW YORK, Sept. 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming Bank of America 37th Annual Investment Conference in San Francisco. Dr. Henderson's presentation will take place on Wednesday, September 19th at 8:30 am PT.

Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)... ... February 15, 2017 , ... ... and Chief Commercial Officer with GenePeeks. Matt is a veteran life sciences ... a computational genomics company focused on identifying inherited disease risk in future generations. ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. („TRIANNI") ... Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung der ... führenden Plattform für die Entdeckung monoklonaler Antikörper. ... neuartiges chimäres Gensegmentdesign aus, das Janssen den ... Antikörpern bietet und das für die schelle Isolierung ...
(Date:2/15/2017)... 15, 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the fourth quarter and full year ended December ... year for Vanda as we continued to demonstrate ... long-term exclusivity for Fanapt," said Mihael H. Polymeropoulos, ... emerging pipeline with important 2017 milestones underscores Vanda,s ...
(Date:2/15/2017)... , Feb. 15, 2017 Windtree Therapeutics, ... focused on developing aerosolized KL4 surfactant therapies for respiratory ... a slide presentation) at 8:00 AM EST on Thursday, ... phase 2 clinical program, the recently announced closing of ... development activities. To participate in the live ...
Breaking Biology Technology:
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... (ctDNA) technologies, today announced that it has signed agreements ... and the Middle East ... milestone marks the first wave of international distribution agreements ... and blood samples. The initial partners will ...
Breaking Biology News(10 mins):